Genentech exercises option to develop Exelixis compound
As a part of agreement, Exelixis will continue to be responsible for the Phase I clinical trial until the point that a maximum tolerated dose (MTD) is determined.

As a part of agreement, Exelixis will continue to be responsible for the Phase I clinical trial until the point that a maximum tolerated dose (MTD) is determined.

Results show that GA 40mg was safe and well-tolerated in ALS patients, however, the study’s primary and secondary endpoints were not met. The study was designed to assess

When delivered topically to the wound, nitric oxide gas (gNO) has a number of known activities believed to be beneficial in the healing of wounds, including antimicrobial and

Timothy Noyes, president and CEO of Proteon, said: “The issuance of this patent further strengthens and broadens Proteon’s elastase vasodilation franchise. With this patent in hand, Proteon Therapeutics

The Advance trial will enroll 1,050 treatment-naive genotype 1 hepatitis C virus (HCV) patients and will evaluate two 24-week telaprevir-based regimens in comparison to a 48-week control arm.

Plicera was generally well-tolerated at all doses evaluated, and no serious adverse events were reported. Glucocerebrosidase (GCase) activity as measured in white blood cells was increased in 20

The clinical validation study will be a blinded study of Power3’s NuroPro diagnostic test, which is a blood test for the detection of Alzheimer’s and Parkinson’s disease. The

As a result, the Spanish group expects to obtain an additional 400,000 of its main raw material, without allocating any internal resources to this, as the operation will

Under the agreement, Sciele acquired Twinject and certain other related Verus products under development for $29 million. Verus may also receive additional payments resulting from the achievement of

The financial terms of the license agreement include an up-front license fee payment to be made by Alphatec Spine to Stout, regulatory and sales milestone payments that could